Ponatinib-induced neutrophilic panniculitis

Journal of Cutaneous Pathology

Volumn 41, Issue 7, 2014, Pages 597-601

  Zhang, May ^a   Hassan, Khaled M ^a   Musiek, Amy ^a   Rosman, Ilana S ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

chronic myeloid leukemia; drug reaction; panniculitis; ponatinib

Indexed keywords

BCR ABL PROTEIN; IMIDAZOLE DERIVATIVE; PONATINIB; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; CASE REPORT; CHEMICALLY INDUCED; FEMALE; HUMAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; NEUTROPHIL; PANNICULITIS; PATHOLOGY;

FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; NEUTROPHILS; PANNICULITIS; PROTEIN KINASE INHIBITORS; PYRIDAZINES;

EID: 84903520834     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/cup.12326     Document Type: Article

References (21)

1. Daley GQ, Van Etten RA, Baltimore D,. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824.
2. Faderl S, Garcia-Manero G, Thomas DA, Kantarjian HM,. Philadelphia chromosome-positive acute lymphoblastic leukemia-current concepts and future perspectives. Rev Clin Exp Hematol 2002; 6: 142.
3. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408.
4. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260.
5. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251.
6. Lamontanara AJ, Gencer EB, Kuzyk O, Hantschel O,. Mechanisms of resistance to BCR-ABL and other kinase inhibitors. Biochim Biophys Acta 2013; 1834: 1449.
7. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367: 2075.
8. Ugurel S, Lahaye T, Hildenbrand R, et al. Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib. Br J Dermatol 2003; 149: 678.
9. Assouline S, Laneuville P, Gambacorti-Passerini C,. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med 2006; 354: 2623.
10. de Masson A, Bouvresse S, Clérici T, Mahé E, Saïag P,. Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib. Ann Dermatol Venereol 2011; 138: 135.
11. Sutra-Loubet C, Carlotti A, Guillemette J, Wallach D,. Neutrophilic panniculitis. J Am Acad Dermatol 2004; 50: 280.
12. Requena L, Sánchez Yus E,. Panniculitis. Part II. Mostly lobular panniculitis. J Am Acad Dermatol 2001; 45: 325.
13. Kwon EJ, Emanuel PO, Gribetz CH, Mudgil AV, Phelps RG,. Poststeroid panniculitis. J Cutan Pathol 2007; 34 (Suppl. 1): 64.
14. de-Andrés-del-Rosario A, Verea-Hernando MM, Yebra-Pimentel MT, Rosende-Maceiras L, Piñeyro-Molina F, Capdevila EF,. Poststeroid panniculitis in an adult. Am J Dermatopathol 2011; 33: e77.
15. Hasegawa M, Sato S, Nakada M, et al. Sweet's syndrome associated with granulocyte colony-stimulating factor. Eur J Dermatol 1998; 8: 503.
16. Llamas-Velasco M, García-Martín P, Sánchez- Pérez J, Fraga J, García-Diez A,. Sweet's syndrome with subcutaneous involvement associated with pegfilgrastim treatment: first reported case. J Cutan Pathol 2013; 40: 46.
17. Kim GH, Levy A, Compoginis G,. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib. J Cutan Pathol 2013; 40: 667.
18. Monfort JB, Pagès C, Schneider P, et al. Vemurafenib-induced neutrophilic panniculitis. Melanoma Res 2012; 22: 399.
19. Zimmer L, Livingstone E, Hillen U, Dömkes S, Becker A, Schadendorf D,. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 2012; 148: 357.
20. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC,. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55: 657.
21. Liu HB, Wu Y, Lv TF, et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 2013; 8: e55128.